The Organoid Company manufactures advanced human organoid models—including CNS, hepatobiliary, kidney, and cardiac—using an automated platform that delivers consistency at scale for drug discovery. Their organoids are immune-competent, available in 96-well formats, and ready for direct drug treatment and single-cell RNA sequencing, enabling researchers to bypass surrogate assays and work directly in disease-relevant human tissue.
Funding
Funding not disclosed
Founders
Product
Problem
Advanced organoid models—among the most powerful tools in drug discovery—have historically been too expensive, too complex, and too slow to produce, limiting their use to a small number of specialized laboratories. This bottleneck prevents most researchers and drug developers from accessing tissue that accurately reflects human disease, forcing them to rely on surrogate assays that delay decisions and reduce confidence in preclinical findings.
Solution
The Organoid Company provides an automated manufacturing platform that produces organoids with unmatched consistency and quality, making advanced organoid technology accessible to a broader range of academic and industry researchers. Their organoids are designed for direct-to-biology workflows, eliminating iterative hand-offs and surrogate assays so drug developers can make faster, more confident decisions in tissue that mirrors human disease. The platform delivers organoids in 96-well formats, ready for drug treatment, single-cell RNA sequencing, and custom analysis, reducing friction from biological question to meaningful answer. By combining high-fidelity models with scalable production, the company removes the historical barriers of cost and complexity that have kept organoid technology a specialist pursuit.
Target Audience
Primary customers are academic and industry researchers in drug discovery and development who need reliable, disease-relevant human tissue models for efficacy, toxicity, and disease mechanism studies.
Features
- Automated manufacturing platform producing organoids with consistent quality and scalability
- Immune-competent CNS organoids with neural rosettes, regional differentiation, neural tube folding, and oligodendrocyte enrichment by week 2, maturing to astrocytes and myelinating oligodendrocytes by day 60–120
- Hepatobiliary organoids containing pericentral and peri-portal hepatocytes, Kupffer cells, stellate cells, and functional bile duct–like structures for fibrosis and drug metabolism studies
- Kidney organoids with segmented nephrons, collecting duct trees, podocytes, and time-dependent tubule maturation
- Cardiac organoids that beat from week 1 for 8+ weeks, composed of 60–70% cardiomyocytes and 10–20% epicardial cells with ECM proteins and vascularization
- All models available in 96-well format ready for drug treatment, scRNAseq, and custom analysis